Bayer cut 12,000 jobs, mostly managers, in a restructuring it calls "Dynamic Shared Ownership." Here is what your pharma and life sciences expertise is worth independently.

Bayer has eliminated over 12,000 employees since 2023, with 3,200 positions cut in 2025 alone, and 1,500 of those in the first quarter of 2025, described explicitly as "mostly managerial roles." The company is targeting $2.3 billion in annual savings by 2026 under CEO Bill Anderson's "Dynamic Shared Ownership" restructuring, which is designed to reduce bureaucracy and flatten the organization. Bayer's three divisions, pharmaceuticals, crop science, and consumer health, have all absorbed cuts, and the managerial layers that coordinated across those divisions have been particularly reduced.

Bayer is under financial pressure from multiple directions. Its pharmaceuticals pipeline has faced patent cliffs and setbacks. Its crop science division absorbed the enormous financial and reputational cost of the Monsanto acquisition and the Roundup litigation that followed. And its consumer health business operates in a low-growth, price-competitive market. The restructuring is partly an attempt to build a leaner, more responsive organization and partly a financial necessity driven by debt load and investor pressure.

The specific focus on managerial roles is notable. Bayer's German corporate culture historically valued structured management hierarchies. Anderson, an American CEO, is explicitly dismantling that structure. The managers being cut built expertise in navigating complex, regulated, international pharmaceutical and agricultural operations. That expertise is in short supply globally.

‍

Pharmaceutical and life sciences consulting is one of the most financially rewarding sectors for independent professionals. The regulatory complexity, the clinical and commercial stakes, and the shortage of experienced practitioners consistently support premium rates.

Medical affairs and regulatory affairs directors from Bayer typically bill $200 to $400 per hour working independently. Pharmaceutical commercial operations leaders advising biotech and specialty pharma companies on market access, pricing strategy, and launch readiness typically work on retainer arrangements of $12,000 to $25,000 per month. Crop science leaders with expertise in agronomy, regulatory compliance, and commercial distribution are in demand from agricultural input companies, agtech startups, and food companies building supply chain traceability programs.

R&D program managers who have operated at Bayer's scale, managing multi-country clinical trials, regulatory submissions, and cross-functional development teams, are sought by smaller biotech and pharmaceutical companies that need that operational capability without the cost of a full-time senior hire. Two retainer clients at $15,000 per month each generates $360,000 annually in gross revenue.

‍

Bayer managers and directors in pharmaceuticals and crop science typically earned $150,000 to $300,000 in total compensation, with significant variation based on division, seniority, and geography. Senior directors and VPs in medical affairs or commercial leadership often reached $280,000 to $450,000.

To set your consulting rate: divide your gross revenue goal (income target plus 30 to 35 percent for taxes and benefits) by expected billable hours. At 900 hours and a gross goal of $260,000, you need to charge approximately $289 per hour, round to $300 and you are priced at a credible market rate for Bayer-level pharmaceutical expertise.

One practical note: in regulated industries, the buying cycle for consulting services is longer than in other sectors because procurement, legal review, and compliance approval add time. Build your pipeline early, expect 60 to 90 days between initial conversation and first invoice, and do not let the runway run low while you wait for approvals to clear.

‍

Bayer trained you in one of the most complex and regulated industries in the world. Whether you worked in pharmaceuticals, crop science, or consumer health, you navigated regulatory environments, global supply chains, and commercial strategies that most professionals never encounter. That specificity is an asset, not a limitation.

The strongest positioning for Bayer professionals is built around the intersection of your domain expertise and the problem a specific buyer is trying to solve. Medical affairs leaders who worked on specific therapeutic areas, cardiovascular, oncology, ophthalmology, are most valuable to companies operating in those same areas. Regulatory affairs directors who built dossiers for European or US submissions are sought by companies preparing their first regulatory filings in those markets.

"I help pharmaceutical companies navigate regulatory approval processes in Europe and the US without the delays that come from teams who have not done it before" is a statement that a biotech CFO or CMO understands immediately. You do not need to explain what medical affairs is. You need to explain what goes wrong without someone like you, and how you prevent that.

‍